Interim Report 2026
Filed with HKEX · Stock code 2268 · · 117 pages · English
Earlier from WuXi XDC Cayman
- WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
- WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
- WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
- WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
- WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
Later from WuXi XDC Cayman
- WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
Follow WuXi XDC Cayman into a list and get an email when it puts out news.
Follow WuXi XDC Cayman